An FDA panel has just upheld these unproven peptides

Peptides progress slowly Closer to the mainstream.

A panel of experts on Thursday recommended by a narrow margin Food and Drug Administration Reclassification four Popular peptides— including one endorsed by podcast host Joe Rogan — to allow some pharmacies to legally distribute them.

In an at times emotionally charged meeting that lasted more than 11 hours, members of the FDA Advisory Committee heard data presentations from FDA staff on four unapproved peptides — BPC-157, KPV, TB-500, and MOTs-C — as well as certification from health care practitioners, patients, pharmacies and clinics.

Members voted eight to six, with one abstention, to add three of the four peptides to the agency’s list in bulk, meaning compounding pharmacies can use them to create personalized medications for patients. (A fourth peptide — MOTs-C — received a seven-to-five vote, with two abstentions.) The advisory committee, which includes several members associated with peptide-related businesses and telehealth clinics, will consider three more peptides on Friday.

Peptide treatments have grown in popularity thanks to endorsements from broadcasters, health influencers and Health and Human Services Secretary Robert F. Kennedy Jr., who said he was a “huge fan.” Peptides, which are essentially smaller versions of proteins, are touted for everything from skin rejuvenation and hair growth to gut health and injury recovery despite a lack of scientific evidence to support these claims.

Many peptides are currently on an unregulated gray market after the Biden administration banned compounding pharmacies from producing 20 peptides over safety concerns in 2023. They can be legally sold online for “research use only” and “not for human consumption,” yet their marketing largely suggests otherwise. China and India are major suppliers of peptides, with some fentanyl labs funded with cryptocurrency Switch gears to produce.

During the meeting, FDA scientists recommended that compounding pharmacies not be allowed to produce any of the seven peptides being considered due to a lack of evidence proving they are safe and effective. Meanwhile, peptide proponents have testified that compounding pharmacies in the United States should be able to produce them so that patients have access to safer, regulated prescription options.

“I’m not going to tell you that the evidence for BPC-157 is strong. It’s not, and I’m not going to overstate it,” said Anant Venjamuri, chief medical officer at telehealth provider Hims & Hers. “What I ask is that you do not read it too weakly as not existing.” The company is actively preparing to launch peptide therapeutics in anticipation of the FDA greenlighting certain peptides.

Among the approved peptides, two are particularly popular with podcasters and influencers. BPC-157 and TB-500 are paired as part of what is called a “Wolverine stack” to help improve recovery after injuries. The panelists were asked to evaluate BPC-157, which is thought to promote tissue repair, for the treatment of ulcerative colitis. World Anti-Doping Agency says BPC-157 It poses a danger to the health of athletes Because it has not been extensively studied in humans.

Some healthcare providers have witnessed their patients turning to the gray market to purchase peptides and ending up with products filled with illicit substances. But while FDA approval may help reduce some of these risks, other commentators said it could create new risks.

Allowing compounds to make these peptides sends a message that the FDA approves them, said John Heritage, president of the Collaborative for Evidence-Based Medicine. “This is very confusing for our patients,” he said, adding that the existence of a gray market is no reason to allow formulators to manufacture these peptides.

There will still be a gray market even if the FDA allows these peptides to be formulated, he said, noting that patients are still looking for gray market GLP-1 drugs even though there are several FDA-approved drugs on the market.